Webinar  

JAK selectivity in RA:
What can we learn from the data?


November 18th 2021
17:00 CET

The Event

JAK selectivity in RA: What can we learn from the data?


This webinar, taking place between 17:00–17:45 CET on Thursday 18 November, will be a stimulating discussion between Prof. Ernest Choy and Prof. Torsten Witte. The expert faculty will examine the immunological rationale for use, mechanism of action and pharmacological profiles of JAK inhibitors in rheumatoid arthritis. In addition, an overview will be detailed on the JAK inhibitors with focus on efficacy and safety. This webinar includes a live Q&A.

Speakers

Professor Ernest Choy
Cardiff University, Cardiff, UK

Professor Ernest Choy is Head of Rheumatology and Translational Research at the Division of Infection and Immunity, and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation Centre at Cardiff University School of Medicine. He is also Honorary Consultant Rheumatologist at the University Hospital of Wales and Clinical Lead of the Welsh Arthritis Research Network. His main research interest is the efficacy of new treatment strategies in rheumatic diseases. He has published widely in major journals and lectures on treatments for rheumatic diseases. 


Professor Torsten Witte
Hannover Medical School, Hanover, Germany 

Professor Torsten Witte is Director and Professor of Rheumatology at the Department of Rheumatology and Immunology, Hannover Medical School. He is a Commission Member at the German Society for Rheumatology, for whom he has been an invited speaker for several years. His main research interests are the identification of new autoantibodies as markers of connective tissue diseases and other chronic inflammatory disorders, and the role of gut microbiota in the induction of reactive arthritis. He has published widely in major journals and lectures on treatments for rheumatic diseases. 

Info

Supporting materials

Related
Events

Towards holistically approaching remission in IBD

Raising the bar: incorporating patient preferences in treatment decisions for RA  

Are all JAK inhibitors the same?